Sort
48,018 grants matching “immunotherapy”
Genetic Approaches to Cancer Immunotherapy
$2,081,408Michel Sadelain · Sloan-Kettering Inst Can Research · P01 · FY2010 · CA
Off-the-Shelf Immune Effector Cells for Hematological Malignancies
$2,080,518John E Wagner · University Of Minnesota · P01 · FY2025 · CA
Innate Immunity: Elucidation and Modulation for Cancer Therapy
$2,080,062Michael A Caligiuri · Ohio State University · P01 · FY2010 · CA
Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.
$2,079,438Christopher Hourigan · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
$2,078,428Robert C Seeger · Children'S Hospital Of Los Angeles · P01 · FY2019 · CA
SAN DIEGO AIDS CLINICAL TRIAL UNIT
$2,078,195University Of California San Diego · U01 · FY2003 · AI
Th1 polarizing immune responses using DNA origami
$2,077,682William M Shih · Harvard University · U54 · FY2019 · CA
Structure and function of eukaryotic DNA transposases
$2,077,429Fred Dyda · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
Mechanisms Underlying Clearance of Persistent Infections
$2,076,662Dorian McGavern · National Institute Of Neurological Disorders And Stroke · ZIA · FY2012 · NS
SPORE in Lymphoma
$2,075,728Helen E Heslop · Baylor College Of Medicine · P50 · FY2024 · CA
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge
$2,074,913Brenda Marie Sandmaier · Fred Hutchinson Cancer Center · P01 · FY2023 · CA
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge
$2,074,913Brenda Marie Sandmaier · Fred Hutchinson Cancer Center · P01 · FY2025 · CA
NK cells, their receptors and unrelated donor transplant
$2,074,355Jeffrey S Miller · University Of Minnesota · P01 · FY2014 · CA
Computational studies of cancer immunotherapy
$2,073,990Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Nanosystems Biology Cancer Center
$2,073,361James R. Heath · Institute For Systems Biology · U54 · FY2018 · CA
Characterization and Enhancement of Anti-Tumor Immune Responses in Head and Neck Cancer
$2,073,213Clint Allen · National Institute On Deafness And Other Communication Disorders · ZIA · FY2020 · DC
Center for Applied Immunology and Pathological Processes
$2,072,692Andrew D Yurochko · Louisiana State Univ Hsc Shreveport · P20 · FY2024 · GM
Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge
$2,071,892Brenda Marie Sandmaier · Fred Hutchinson Cancer Center · P01 · FY2022 · CA
PATHOGENESIS AND TREATMENT OF ACUTE HIV INFECTION
$2,071,775Massachusetts General Hospital · U01 · FY2002 · AI
Growth Factor Imaging and Photoimmunotherapy
$2,071,751Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
The University of Texas MD Anderson Cancer Center SPORE in Melanoma
$2,070,386Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Melanoma and Skin Cancer Program SPORE
$2,070,180Hassane M Zarour · University Of Pittsburgh At Pittsburgh · P50 · FY2022 · CA
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
$2,069,846Roy S Herbst · Yale University · P50 · FY2023 · CA
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
$2,069,565Steven Mark Albelda · University Of Pennsylvania · P01 · FY2019 · CA
Preclinical drug development in pancreatic cancer
$2,069,338Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA